Arne Scholz
Overview
Explore the profile of Arne Scholz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagemann U, Schatz C, Suominen M, Schlicker A, Knuuttila M, Wilson T, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769434
Despite treatment, prostate cancer commonly progresses into castration-resistant prostate cancer (CRPC), which remains largely incurable, requiring the development of new interventions. Darolutamide is an orally administered second-generation androgen receptor inhibitor...
2.
Suominen M, Knuuttila M, Sjoholm B, Wilson T, Alhoniemi E, Mumberg D, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627143
An increased risk of non-pathological fractures in patients with prostate cancer and bone metastases has been associated with combination treatment with radium-223, abiraterone, and prednisone/prednisolone in the absence of bone-protecting...
3.
Suominen M, Knuuttila M, Schatz C, Schlicker A, Vaaraniemi J, Sjoholm B, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768509
Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor...
4.
Karlsson J, Schatz C, Wengner A, Hammer S, Scholz A, Cuthbertson A, et al.
Front Med (Lausanne)
. 2023 Feb;
9:1071086.
PMID: 36726355
Targeted alpha therapy (TAT) is a promising approach for addressing unmet needs in oncology. Inherent properties make α-emitting radionuclides well suited to cancer therapy, including high linear energy transfer (LET),...
5.
Lucking U, Kosemund D, Bohnke N, Lienau P, Siemeister G, Denner K, et al.
J Med Chem
. 2021 Jul;
64(15):11651-11674.
PMID: 34264057
Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development,...
6.
Suominen M, Maki-Jouppila J, Huhtinen A, Sjoholm B, Rissanen J, Luostarinen A, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34070363
Osteolytic bone disease is a hallmark of multiple myeloma (MM) mediated by MM cell proliferation, increased osteoclast activity, and suppressed osteoblast function. The proteasome inhibitor bortezomib targets MM cells and...
7.
Hammer S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, Hagemann U, Scholz A, et al.
Clin Cancer Res
. 2021 May;
27(15):4367-4378.
PMID: 34035067
Purpose: Androgen receptor (AR) inhibitors are well established in the treatment of castration-resistant prostate cancer and have recently shown efficacy also in castration-sensitive prostate cancer. Although most patients respond well...
8.
Wengner A, Scholz A, Haendler B
Int J Mol Sci
. 2020 Nov;
21(21).
PMID: 33158305
Steroid hormone signaling induces vast gene expression programs which necessitate the local formation of transcription factories at regulatory regions and large-scale alterations of the genome architecture to allow communication among...
9.
Hagemann U, Wickstroem K, Hammer S, Bjerke R, Zitzmann-Kolbe S, Ryan O, et al.
Cancer Biother Radiopharm
. 2020 Apr;
35(7):497-510.
PMID: 32255671
Targeted α therapy (TAT) offers the potential for the targeted delivery of potent α-particle-emitting radionuclides that emit high linear energy transfer radiation. This leads to a densely ionizing radiation track...
10.
Morris M, Corey E, Guise T, Gulley J, Kelly W, Quinn D, et al.
Nat Rev Urol
. 2019 Nov;
16(12):745-756.
PMID: 31712765
The targeted alpha therapy radium-223 (Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases. Preclinical studies demonstrate that...